Serum tetranectin as a preoperative indicator for postoperative complications in Danish ovarian cancer patients
- PMID: 20304468
- DOI: 10.1016/j.ygyno.2010.02.023
Serum tetranectin as a preoperative indicator for postoperative complications in Danish ovarian cancer patients
Abstract
Objective: The association between tetranectin (TN) and selected lifestyle factors (smoking and alcohol) and the postoperative complication rate for ovarian cancer (OC) patients undergoing primary cytoreductive surgery has not yet been characterized. The aim of the study was to examine the value of TN, smoking and alcohol as indicators of postoperative complications in OC patients.
Methods: Serum TN was measured for 374 OC patients undergoing primary cytoreductive surgery. In addition, they reported their smoking and alcohol status. The prognostic value of variables was found with univariate and multivariate analyses using logistic regression analysis.
Results: In univariate analysis TN was the only one out of 8 variables that significantly predicted postoperative complications (OR=0.55 (95% CI: 0.34-0.87), P=0.01). High preoperative serum TN was associated with a low risk of postoperative complications. Stepwise reduction of the multivariate model demonstrated that TN and histology were the only significant co-variables (TN, OR=0.51 (95% CI: 0.32-0.83), P=0.006; histology, OR=1.70 (95% CI: 1.02-2.82), P=0.041). TN was the only indicator, which was statistical significant in both univariate and multivariate analyses.
Conclusion: Preoperative serum TN is a significant indicator of postoperative complications in Danish OC patients and deserves to be validated in larger future studies.
Copyright 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Serum tetranectin is a significant prognostic marker in ovarian cancer patients.Acta Obstet Gynecol Scand. 2010;89(2):190-8. doi: 10.3109/00016340903530936. Acta Obstet Gynecol Scand. 2010. PMID: 20121334
-
The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer.Anticancer Res. 2002 May-Jun;22(3):1765-8. Anticancer Res. 2002. PMID: 12168866
-
Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.Gynecol Oncol. 2009 May;113(2):221-7. doi: 10.1016/j.ygyno.2009.01.020. Epub 2009 Mar 3. Gynecol Oncol. 2009. PMID: 19261323
-
The prognostic value of pretherapeutic tetranectin and CA-125 in patients with relapse of ovarian cancer.Gynecol Oncol. 2000 Dec;79(3):416-9. doi: 10.1006/gyno.2000.5996. Gynecol Oncol. 2000. PMID: 11104612
-
Insight into the function of tetranectin in human diseases: A review and prospects for tetranectin-targeted disease treatment.Heliyon. 2023 Dec 10;10(1):e23512. doi: 10.1016/j.heliyon.2023.e23512. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38187250 Free PMC article. Review.
Cited by
-
Tetranectin as a Potential Biomarker for Stable Coronary Artery Disease.Sci Rep. 2015 Dec 1;5:17632. doi: 10.1038/srep17632. Sci Rep. 2015. PMID: 26621497 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical